Tags

Type your tag names separated by a space and hit enter

Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders.
Curr Alzheimer Res. 2016; 13(8):879-86.CA

Abstract

BACKGROUND

Preclinical studies have shown that lithium modifies pathological cascades implicated in certain neurodegenerative disorders, such as Alzheimer's disease (AD), Huntigton`s disease (HD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS). A critical question is whether these pharmacodynamic properties of lithium translate into neurodegenerative diseases modifying effects in human subjects.

METHODS

We reviewed all English controlled clinical trials published in PubMed, PsycINFO, Embase, SCOPUS, ISI-Web with the use of lithium for the treatment of neurodegenerative disorders between July 2004 and July 2014.

RESULTS

Lithium showed evidence for positive effects on cognitive functions and biomarkers in amnestic mild cognitive impairment (aMCI, 1 study) and AD (2 studies), even with doses lower than those used for mood stabilisation. Studies of Li in HD, MSA and CSI did not show benefits of lithium. However, due to methodological limitations and small sample size, these studies may be inconclusive. Studies in ALS showed consistently negative results and presented evidence against the use of lithium for the treatment of this disease.

CONCLUSION

In absence of disease modifying treatments for any neurodegenerative disorders, the fact that at least 3 studies supported the effect of lithium in aMCI/AD is noteworthy. Future studies should focus on defining the dose range necessary for neuroprotective effects to occur.

Authors+Show Affiliations

Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo. Rua Dr. Ovídio Pires de Campos 785, 05403-010 - São Paulo, SP, Brazil.. forlenza@usp.br.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26892289

Citation

Forlenza, Orestes V., et al. "Lithium, a Therapy for AD: Current Evidence From Clinical Trials of Neurodegenerative Disorders." Current Alzheimer Research, vol. 13, no. 8, 2016, pp. 879-86.
Forlenza OV, Aprahamian I, de Paula VJ, et al. Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders. Curr Alzheimer Res. 2016;13(8):879-86.
Forlenza, O. V., Aprahamian, I., de Paula, V. J., & Hajek, T. (2016). Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders. Current Alzheimer Research, 13(8), 879-86.
Forlenza OV, et al. Lithium, a Therapy for AD: Current Evidence From Clinical Trials of Neurodegenerative Disorders. Curr Alzheimer Res. 2016;13(8):879-86. PubMed PMID: 26892289.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders. AU - Forlenza,Orestes V, AU - Aprahamian,Ivan, AU - de Paula,Vanessa J, AU - Hajek,Tomas, PY - 2015/09/10/received PY - 2015/10/30/revised PY - 2015/11/13/accepted PY - 2016/2/20/entrez PY - 2016/2/20/pubmed PY - 2017/10/3/medline SP - 879 EP - 86 JF - Current Alzheimer research JO - Curr Alzheimer Res VL - 13 IS - 8 N2 - BACKGROUND: Preclinical studies have shown that lithium modifies pathological cascades implicated in certain neurodegenerative disorders, such as Alzheimer's disease (AD), Huntigton`s disease (HD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS). A critical question is whether these pharmacodynamic properties of lithium translate into neurodegenerative diseases modifying effects in human subjects. METHODS: We reviewed all English controlled clinical trials published in PubMed, PsycINFO, Embase, SCOPUS, ISI-Web with the use of lithium for the treatment of neurodegenerative disorders between July 2004 and July 2014. RESULTS: Lithium showed evidence for positive effects on cognitive functions and biomarkers in amnestic mild cognitive impairment (aMCI, 1 study) and AD (2 studies), even with doses lower than those used for mood stabilisation. Studies of Li in HD, MSA and CSI did not show benefits of lithium. However, due to methodological limitations and small sample size, these studies may be inconclusive. Studies in ALS showed consistently negative results and presented evidence against the use of lithium for the treatment of this disease. CONCLUSION: In absence of disease modifying treatments for any neurodegenerative disorders, the fact that at least 3 studies supported the effect of lithium in aMCI/AD is noteworthy. Future studies should focus on defining the dose range necessary for neuroprotective effects to occur. SN - 1875-5828 UR - https://www.unboundmedicine.com/medline/citation/26892289/Lithium_a_Therapy_for_AD:_Current_Evidence_from_Clinical_Trials_of_Neurodegenerative_Disorders_ L2 - http://www.eurekaselect.com/139630/article DB - PRIME DP - Unbound Medicine ER -